HAVN Life Sciences Inc.
HAVN.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$291.41K
Close$
Share Statistics
| Market cap | $291,413.00 |
|---|---|
| Enterprise Value | $303,661.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.25 |
| Beta | -0.66 |
| Outstanding Shares | 9,713,755 |
Return
| Return on Equity | -3909.16% |
|---|---|
| Return on Assets | -2376.31% |
| Return on Invested Capital | -1926.48% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | -0.02 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HAVN Life Sciences Inc.
6 employees
CEO: Tim Moore HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-co...